Barkley RA (1997). Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 12: 65–94.
Bos DJ, Oranje B, Veerhoek E, Van Diepen RM, Weusten JM, Demmelmair H et al (2015). Reduced symptoms of inattention after dietary omega-3 fatty acid supplementation in boys with and without attention deficit/hyperactivity disorder. Neuropsychopharmacology 40: 2298–2306.
Burgess JR, Stevens L, Zhang W, Peck L (2000). Long-chain polyunsaturated fatty acids in children with attention-deficit hyperactivity disorder. Am J Clin Nutr 17(suppl): 327S–330S.
Chang JP, Chang SS, Yang HT, Palani M, Chen CP, Su KP (2015). Polyunsaturated fatty acids (PUFAs) levels in patients with cardiovascular diseases (CVDs) with and without depression. Brain Behav Immun 44: 28–31.
Chang JP, Jiling L, Huang YT, Lu YJ, Su KP (2016). Delay aversion, temporal processing, and N-3 fatty acids intake in childrne with attention- deficit/hyperactivity disorder (ADHD). Clin Psychol 4: 1094–1103.
Chang JP, Lai HC, Yang HT, Su WP, Peng CY, Galecki P et al (2017). Polyunsaturated fatty acids levels and initial presentation of somatic symptoms induced by interferon-alpha therapy in patients with chronic hepatitis C viral infection. Nutr Neurosci 20: 291–296.
Chang JP, Su KP (2010). The lipid raft hypothesis: the relation among omega-3 fatty acids, depression, and cardiovascular diseases. Taiwan J Psychiatry 24: 168–180.
Chen JR, Hsu SF, Hsu CD, Hwang LH, Yang SC (2004). Dietary patterns and blood fatty acid composition in children with attention-deficit hyperactivity disorder in Taiwan. J Nutr Biochem 15: 467–472.
Chiu CC, Su KP, Cheng TC, Liu HC, Chang CJ, Dewey ME et al (2008). The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 32: 1538–1544.
The Cochrane Collaboration (2014). Review Manager (RevMan) [Computer program]: Version 5.3. Copenhagen: The Nordic Cochrane Centre..
Colter AL, Cutler C, Meckling KA (2008). Fatty acid status and behavioural symptoms of attention deficit hyperactivity disorder in adolescents: A case-control study. Nutr J 7: 8.
Connor WE, Neuringer M, Lin DS (1990). Dietary effects on brain fatty acid composition: the reversibility of n-3 fatty acid deficiency and turn-over of docosahexaenoic acid in the brain, erythrocytes, and plasma of rhesus monkeys. J Lipid Res 31: 237–247.
Cooper RE, Tye C, Kuntsi J, Vassos E, Asherson P (2015). Omega-3 polyunsaturated fatty acid supplementation and cognition: a systematic review and meta-analysis. J Psychopharmacol 29: 753–763.
Das UN (2006). Essential fatty acids: biochemistry, physiology and pathology. Biotechnol J 1: 420–439.
Donfrancesco R, Nativio P, Borrelli E, Giua E, Andriola E, Villa MP et al (2016). Serum cytokines in paediatric neuropsychiatric syndromes: focus on attention deficit hyperactivity disorder. Minerva Pediatr Epub ahead of print.
Foster JD, Adkins SD, Lever JR, Vaughan RA (2008). Phorbol ester induced trafficking-independent regulation and enhanced phosphorylation of the dopamine transporter associated with membrane rafts and cholesterol. J Neurochem 105: 1683–1699.
Germano M, Meleleo D, Montorfano G, Adorni L, Negroni M, Berra B et al (2007). Plasma, red blood cells phospholipids and clinical evaluation after long chain omega-3 supplementation in children with attention deficit hyperactivity disorder (ADHD). Nutr Neurosci 10: 1–9.
Gillies D, Sinn J, Lad SS, Leach MJ, Ross MJ (2012). Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev CD007986.
Gow RV, Matsudaira T, Taylor E, Rubia K, Crawford M, Ghebremeskel K et al (2009). Total red blood cell concentrations of omega-3 fatty acids are associated with emotion-elicited neural activity in adolescent boys with attention-deficit hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 80: 151–156.
Gow RV, Vallee-Tourangeau F, Crawford MA, Taylor E, Ghebremeskel K, Bueno AA et al (2013). Omega-3 fatty acids are inversely related to callous and unemotional traits in adolescent boys with attention deficit hyperactivity disorder. Prostaglandins Leukotr Essent Fatty Acids 88: 411–418.
Gustafsson PA, Birberg-Thornberg U, Duchen K, Landgren M, Malmberg K, Pelling H et al (2010). EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. Acta Paediatrica 99: 1540–1549.
Hariri M, Djazayery A, Djalali M, Saedisomeolia A, Rahimi A, Abdolahian E (2012). Effect of n-3 supplementation on hyperactivity, oxidative stress and inflammatory mediators in children with attention-deficit-hyperactivity disorder. Malays J Nutr 18: 329–335.
Hawkey E, Nigg JT (2014). Omega-3 fatty acid and ADHD: blood level analysis and meta-analytic extension of supplementationtrials. Clin Psychol Rev 34: 496–505.
Hibbeln JR, Davis JM, Steer C, Emmett P, Rogers I, Williams C et al (2007). Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an observational cohort study. Lancet 369: 578–585.
Ishikua Y, Ikeda G, Akimoto K, Hata M, Kusumoto A, Kidokoro A et al (2009). Arachidonic acid supplementation decreased P300 latency and increases P300 amplitude of event-related potentioals in healthy elderly men. Neuropsychobiology 60: 73–79.
Kinsella JE, Broughton KS, Whelan JW (1990). Dietary unsaturated fatty acid: interactions and possible needs in relation to eicosanoids synthesis. J Nutr Biochem 9: 123–141.
Lapillonne A, DeMar JC, Nannegari V, Heird WC (2002). The fatty acid profile of buccal cheek cell phospholipids is a noninvasive marker of long-chain polyunsaturated fatty acid status in piglets. J Nutr 132: 2319–2323.
Lin PY, Chang CH, Chong MF, Chen H, Su KP (2017). Polyunsaturated fatty cids in perinatal depression: a systematic review and meta-analysis. Biol Psychiatry Epub ahead of print.
Lin PY, Huang SY, Su KP (2010). A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol Psychiatry 68: 140–147.
Lin PY, Su KP (2007). A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry 68: 1056–1061.
Manor I, Magen A, Keidar D, Rosen S, Tasker H, Cohen T et al (2012). The effect of phosphatidylserine containing Omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. Eur Psychiatry 27: 335–342.
Milte CM, Sinn N, Buckley JD, Coates AM, Young RM, Howe PR (2011). Polyunsaturated fatty acids, cognition and literacy in children with ADHD with and without learning difficulties. J. Child Health Care 15: 299–311.
Mitchell EA, Aman MG, Turbott SH, Manku M (1987). Clinical characteristics and serum essential fatty acid levels in hyperactive children. Clin Pediatr (Phila) 26: 406–411.
Moher D, Liberati A, Tetzlaff J, Altman DG (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62: 1006–1012.
Narad ME, Garner AA, Peugh JL, Tamm L, Antonini TN, Kingery KM et al (2015). Parent-teacher agreement on ADHD symptoms across development. Psychol Assess 27: 239–248.
Okaichi Y, Ishikua Y, Akimoto K, Kawashima H, Toyoda-Ono Y, Kiso Y et al (2005). Arachidonic acid improves aged rats’ spatial cognition. Physiol Behav 84: 617–623.
Perera H, Jeewandara KC, Seneviratne S, Guruge C (2012). Combined omega3 and omega6 supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: A double-blind, placebo-controlledstudy. J Child Neurol 27: 747–753.
Pliszka SR, Crismon ML, Hughes CW, Corners CK, Emslie GJ, Jensen PS et al (2006). The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45: 642–657.
Puri BK, Martins JG (2014). Which polyunsaturated fatty acids are active in children with attention-deficit hyperactivity disorder receiving PUFA supplementation? A fatty acid validated meta-regression analysis of randomized controlled trials. Prostaglandins Leukot Essent Fatty Acids 90: 179–189.
Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD et al (2007). Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder—a preliminary tolerability and efficacy study. Clin Ther 29: 1168–1177.
Rapaport MH, Nierenberg AA, Schettler PJ, Kinkead B, Cardoos A, Walker R et al (2016). Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol Psychiatry 21: 71–79.
Richardson AJ, Puri BK (2002). A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Progress Neuropsychopharmacol Biol Psychiatry 26: 233–239.
Shadish WR (1994) Combining estimates of the effect size. In: Cooper HHLV (eds) The Handbook of Research Synthesis. Russell Sage Foundation: New York. pp 261–281.
Sinn N, Bryan J, Wilson C (2008). Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: a randomised controlled trial. Prostaglandins Leukot Essent Fatty Acids 78: 311–326.
Sonuga-Barke EJ, Brandeis D, Cortese S, Daley D, Ferrin M, Holtmann M et al (2013). Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. Am J Psychiatry 170: 275–289.
Stark KD (2008). The percentage of n-3 highly unsaturated fatty acids in total HUFA as biomarker for omega-3 fatty acid status in tissues. Lipids 43: 45–53.
Stata Corp. Stata Statistical Software: Release 11. StataCorp LP: College Station, TX, USA, 2009..
Stevens L, Zhang W, Peck L, Kuczek T, Grevstad N, Mahon A et al (2003). EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids 38: 1007–1021.
Stevens LJ, Zentall SS, Deck JL, Abate ML, Watkins BA, Lipp SR et al (1995). Essential fatty-acid metabolism in boys with attention-deficit hyperactiviyt disorder. American J Clin Nutr 62: 761–768.
Su KP, Huang SY, Chiu CC, Shen WW (2003). Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 13: 267–271.
Su KP, Huang SY, Chiu TH, Huang KC, Huang CL, Chang HC et al (2008). Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 69: 644–651.
Su KP, Huang SY, Peng CY, Lai HC, Huang CL, Chen YC et al (2010). Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels. Biol Psychiatry 67: 550–557.
Su KP, Lai HC, Yang HT, Su WP, Peng CY, Chang JP et al (2014). Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial. Biol Psychiatry 76: 559–566.
Sun Q, Ma J, Campos H, Hankinson SE, Hu FB (2007). Comparison between plasma and erythrocyte fatty acid content as biomarkers of fatty acid intake in US women. Am J Clin Nutr 86: 74–81.
The MTA Cooperative Group (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56: 1073–1086.
Vaisman N, Kaysar N, Zaruk-Adasha Y, Pelled D, Brichon G, Zwingelstein G et al (2008). Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: effect of dietary n-3 fatty acids containing phospholipids. Am J Clin Nutr 87: 1170–1180.
Valentine JC, Pigott TD, Rothstein HR (2010). How many studies do you need? A primer on statistical power for meta-analysis. J Educ Behav Stat 35: 215–247.
Voigt RG, Llorente AM, Jensen CL, Fraley JK, Berretta MC, Heird WC (2001). A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J Pediatr 139: 189–196.
Widenhorn-Muller K, Schwanda S, Scholz E, Spitzer M, Bode H (2014). Effect of supplementation with long-chain omega-3 polyunsaturated fatty acids on behavior and cognition in children with attention deficit/hyperactivity disorder (ADHD): A randomized placebo-controlled intervention trial. Prostaglandins Leukot Essent Fatty Acids 91: 49–60.